Abstract

The application relates to a method for predicting a risk for preeclampsia in a subject, said method comprising analysing a sample from the subject for the level of expression of miR455 and comparing the level of expression of miR455 in the sample from the subject to the levels of miR455 in a control sample, wherein a significantly lower expression of miR455 as compared to the expression of miR455 in the control is indicative of a risk for preeclampsia.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

A bioreactor for preferably three-dimensional cell culturing comprises a scaffold chamber, a first tube, a second tube and a first valve with a scaffold adapter, a tube adapter and a medium adapter. The first valve has a housing with a longitudinal female portion ending in an opening and a longitudinal actuator being arranged through the opening of the female portion of the housing such that the actuator is arranged partially inside the housing and partially outside the housing, wherein the actuator of the first valve is axially moveable relative to the housing of the first valve between a first position in which the first valve is in the operation position and a second position in which the first valve is in the medium change position. By providing the actuators in the first valve which is applied by axial movements, operation of the bioreactor can be comparably simple and safe. In particular, such arrangement allows for a comparably easy identification of the position of the first valve, i.e., e.g., if the valve is in the medium change position or in the operation position. Furthermore, it also allows for exactly adjusting the position of the actuator such that also positions in between the medium change position and the operation position can be conveniently applied if necessary.

IPC Classes  ?

• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

The present invention relates to a reliable method of prediction of lower respiratory tract infection or inflammation in humans, wherein the level of pancreatic stone protein / regenerating protein (PSP/reg) is determined in serum, and a high level is indicative of the development and the severity of the disease, allowing the classification of patients according to risk.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

SRIF peptide antagonists, which are selective for SSTR2 in contrast to the other cloned SRIF receptors and which bind with high affinity to the cloned human receptor SSTR2 but do not activate the receptor, have many useful functions. Because they do not bind with significant affinity to SSTR1, SSTR3, SSTR4 or SSTR5, their administration avoids potential undesirable side effects. By incorporating radioiodine or the like in these SSTR2-selective SRIF antagonists, a labeled compound useful in drug-screening methods is provided. Alternatively, for use in therapy, highly radioactive moieties can be N-terminally coupled, complexed or chelated thereto. Because they block the receptor function, they can be used therapeutically to block certain physiological effects which SSTR2 mediates.

IPC Classes  ?

• A61K 38/31 - Somatostatins
• A61K 3/10 -
• A61K 7/12 -

Abstract

The present invention relates to a method for treating cancer, for instance brain tumors, in a subject by inhibiting spleen tyrosine kinase (Syk) by administering to said subject a therapeutically effective amount of a modulator of Syk, for example a specific antibody or a siRNA. The present invention also encompasses methods of diagnosing cancer by measuring levels of Syk, as well as method of targeted therapy using anti-Syk antibodies conjugated to therapeutic agents.

IPC Classes  ?

• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention relates to a method for treating cancer in a subject using a mTOR inhibitor in combination with a therapeutically effective amount of a modulator of a MNK.

IPC Classes  ?

• A61K 31/436 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A61K 31/45 - Non-condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide

Abstract

The application relates to methods for determining whether or not antiviral therapies will be effective. In particular, the present application provides a method using miRNA, e.g. miR-122 or miR-296-5p, for determining the likelihood that a subject having a viral infection of the liver will be responsive to antiviral therapy that includes stimulation of Interferon (IFN) activity, and kits for the performance of said determination.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids

Abstract

The application relates to treatments for improving antiviral therapies and to method for determining whether or not antiviral therapies wilt be effective. In particular, the present application provides a method for determining the likelihood that a subject having a viral infection of the liver will be responsive to antiviral therapy that includes stimulation of Interferon (IFN) activity, and kits for the performance of said determination.

IPC Classes  ?

• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• G01N 33/576 - ImmunoassayBiospecific binding assayMaterials therefor for hepatitis

Abstract

Described herein are somatostatin analogs that are receptor antagonists of the somatostatin receptor, including SSTR2-selective antagonists. Related compounds, kits and methods, including antagonists complexed with or conjugated to radioactive nuclides and uses thereof. The antagonists of the invention are useful in diagnosing and treating neoplastic and non-neo-plasticmammalian diseases.

IPC Classes  ?

• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 14/655 - Somatostatins

Abstract

Described herein are somatostatin analogs that are receptor antagonists of the somatostatin receptor, including SSTR2-selective antagonists. Related compounds, kits and methods, including antagonists complexed with or conjugated to radioactive nuclides and uses thereof. The antagonists of the invention are useful in diagnosing and treating neoplastic and non-neoplastic mammalian diseases.

IPC Classes  ?

• C07K 14/655 - Somatostatins
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids

Abstract

The application relates to treatments for improving antiviral therapies and to method for determining whether or not antiviral therapies will be effective. In particular, the present application provides a method for determining the likelihood that a subject having a viral infection of the liver will be responsive to antiviral therapy that includes stimulation of Interferon ( IFN) activity, and kits for the performance of said determination.

IPC Classes  ?

• G01N 33/576 - ImmunoassayBiospecific binding assayMaterials therefor for hepatitis
• C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
• A61P 31/12 - Antivirals

Abstract

This invention relates to targetable vesicles and targetable vesicle-based contrast agents imaging in clinical medicine including in vitro and in vivo imaging. Enzyme nanoreactors having polymer membranes are used to precipitate highly insoluble nanoparticles inside the vesicles. Surface modification with targeting moieties such as the macrophage scavenger receptor A1 (SRA-1) ligand polyguanylic acid and fluorescence-labeled streptavidin provides bimodal target-specific vesicles providing contrast for medical imaging such as MR and fluorescence imaging.

IPC Classes  ?

• A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes

Abstract

The present invention relates to the diagnosis, prognosis or predisposition of developing cancer, especially lymphoma. The invention also relates to gene therapy and identification of potential new therapeutic agents for treating cancer such as lymphoma.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

SRIF peptide antagonists, which are selective for SSTR2 in contrast to the other cloned SRIF receptors and which bind with high affinity to the cloned human receptor SSTR2 but do not activate the receptor, have many useful functions. Because they do not bind with significant affinity to SSTR1, SSTR3, SSTR4 or SSTR5, their administration avoids potential undesirable side effects. Because they block the receptor function, they can be used therapeutically to block certain physiological effects which SSTR2 mediates. By incorporating radioiodine or the like in these SSTR2-selective SRIF antagonists, a laebled compound useful in drug-screening methods is provided. Alternatively, for use in therapy, highly radioactive moieties can be N-terminally coupled, complexed or chelated thereto.

IPC Classes  ?

• C07K 14/655 - Somatostatins
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids